A detailed history of Dn B Asset Management As transactions in Cytokinetics Inc stock. As of the latest transaction made, Dn B Asset Management As holds 10,434 shares of CYTK stock, worth $325,645. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,434
Previous 9,213 13.25%
Holding current value
$325,645
Previous $433,000 3.23%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

BUY
$40.19 - $51.12 $49,071 - $62,417
1,221 Added 13.25%
10,434 $419,000
Q4 2024

Feb 12, 2025

BUY
$46.36 - $58.62 $84,653 - $107,040
1,826 Added 24.72%
9,213 $433,000
Q3 2024

Nov 12, 2024

BUY
$51.22 - $60.16 $7,990 - $9,384
156 Added 2.16%
7,387 $390,000
Q2 2024

Jul 05, 2024

BUY
$47.86 - $75.05 $30,869 - $48,407
645 Added 9.79%
7,231 $391,000
Q1 2024

Apr 12, 2024

BUY
$63.75 - $108.06 $419,857 - $711,683
6,586 New
6,586 $461,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $2.94B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Dn B Asset Management As Portfolio

Follow Dn B Asset Management As and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dn B Asset Management As, based on Form 13F filings with the SEC.

News

Stay updated on Dn B Asset Management As with notifications on news.